Amgen Treads Water with Modest Revenue Growth

Amgen Inc., traded on the Nasdaq under ticker AMGN, reported revenue of $33.4 billion in 2025, up 1.8% from $32.8 billion in 2024.

The biotechnology company's net income was $4.0 billion in 2025, compared to $4.1 billion in 2024, showing a slight decrease despite the increase in revenue.

Amgen raised its quarterly dividend to $2.38 per share in 2025, implying an annualized payout of $9.52 per share, up from $9.00 previously.

The company's late-stage pipeline remains a key area of focus, with multiple programs aimed at oncology, inflammation, and cardiovascular disease.